Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Analysts at Chardan Capital

Chardan Capital assumed coverage on shares of Palvella Therapeutics (NASDAQ:PVLAFree Report) in a research report released on Wednesday morning, Marketbeat reports. The brokerage issued a buy rating and a $50.00 target price on the stock.

A number of other analysts have also recently issued reports on the stock. TD Cowen assumed coverage on shares of Palvella Therapeutics in a research note on Wednesday, February 5th. They issued a “buy” rating and a $44.00 target price for the company. Jones Trading initiated coverage on shares of Palvella Therapeutics in a research note on Tuesday, March 25th. They issued a “buy” rating and a $45.00 price objective for the company. Scotiabank initiated coverage on shares of Palvella Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price target on shares of Palvella Therapeutics in a research report on Tuesday, April 1st. Finally, Stifel Nicolaus assumed coverage on Palvella Therapeutics in a report on Wednesday, March 26th. They set a “buy” rating and a $45.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Palvella Therapeutics currently has an average rating of “Buy” and an average price target of $44.43.

View Our Latest Research Report on PVLA

Palvella Therapeutics Stock Performance

Shares of PVLA stock opened at $21.76 on Wednesday. The firm has a market cap of $239.77 million, a price-to-earnings ratio of -1.80 and a beta of 0.10. Palvella Therapeutics has a fifty-two week low of $6.20 and a fifty-two week high of $29.27. The business has a 50-day moving average price of $22.57.

Insider Transactions at Palvella Therapeutics

In other Palvella Therapeutics news, Director George M. Jenkins acquired 2,500 shares of Palvella Therapeutics stock in a transaction dated Wednesday, April 9th. The stock was bought at an average cost of $20.13 per share, with a total value of $50,325.00. Following the completion of the transaction, the director now owns 183,171 shares of the company’s stock, valued at $3,687,232.23. The trade was a 1.38 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.39% of the stock is currently owned by corporate insiders.

Institutional Trading of Palvella Therapeutics

A number of hedge funds have recently bought and sold shares of PVLA. Suvretta Capital Management LLC acquired a new position in shares of Palvella Therapeutics during the fourth quarter valued at about $8,574,000. BVF Inc. IL acquired a new position in Palvella Therapeutics in the 4th quarter valued at approximately $8,359,000. Samsara BioCapital LLC acquired a new position in Palvella Therapeutics in the 4th quarter valued at approximately $8,154,000. Frazier Life Sciences Management L.P. bought a new stake in shares of Palvella Therapeutics in the 4th quarter worth approximately $7,847,000. Finally, Adams Street Partners LLC acquired a new stake in shares of Palvella Therapeutics during the 4th quarter worth approximately $4,916,000. 40.11% of the stock is owned by institutional investors.

About Palvella Therapeutics

(Get Free Report)

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.

See Also

Analyst Recommendations for Palvella Therapeutics (NASDAQ:PVLA)

Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.